-
-
-
-
-
-
-
Karyopharm Therapeutics (KPTI) Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting
-
-
-
-
-
-
-
Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
-
-
-
-
-
-
-
Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
-
-
-
-
-
-
-
Karyopharm Therapeutics (KPTI) Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19
-
-
-
-
-
-
-
Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
-
-
-
-
-
-
-
Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Karyopharm Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three
-
15,614 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

